Código QR

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

BackgroundNeoadjuvant checkpoint inhibition (CPI) has recently demonstrated impressive outcomes in patients with stage 3 cutaneous melanoma. However, the safety, efficacy, and outcome of neoadjuvant CPI in patients with mucosal melanoma (MM) are not well studied as MM is a rare melanoma subtype. CPI...

Descripción completa

Guardado en:
Autores principales: Joel Ho, Jane Mattei, Michael Tetzlaff, Michelle D. Williams, Michael A. Davies, Adi Diab, Isabella C. Glitza Oliva, Jennifer McQuade, Sapna P. Patel, Hussein Tawbi, Michael K. Wong, Sarah B. Fisher, Ehab Hanna, Emily Z. Keung, Merrick Ross, Roi Weiser, Shirley Y. Su, Michael Frumovitz, Larissa A. Meyer, Amir Jazaeri, Curtis A. Pettaway, B. Ashleigh Guadagnolo, Andrew J. Bishop, Devarati Mitra, Ahsan Farooqi, Roland Bassett, Silvana Faria, Priyadharsini Nagarajan, Rodabe N. Amaria
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2022-10-01
Colección:Frontiers in Oncology
Materias:
mucosal melanoma
immunotherapy
melanoma
neoadjuvant
resectable
Acceso en línea:https://www.frontiersin.org/articles/10.3389/fonc.2022.1001150/full
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares